Overall this study has demonstrated that zebrafish embryos naturally infected with bioluminescent 36 M. marinum M can be used for the rapid screening of anti-mycobacterial compounds with readily 37 available equipment and limited expertise. The result is an assay that can be carried out by a wide 38 variety of laboratories for minimal cost and without high levels of zebrafish expertise. 39 40
Synopsis
population, resulting in approximately 1.5 million deaths per year. Due to the difficulties and 23 expense of carrying out animal drug trials using M. tuberculosis and rodents, infections of the 24 zebrafish Danio rerio with M. marinum have been used as a surrogate. However the methods so far 25 described require specialised equipment and a high level of operator expertise. 26
We investigated a natural infection model where zebrafish embryos are infected through incubation 27 in media containing M. marinum. Using bioluminescently labelled M. marinum, we have 28 characterised the nature of infection and established a model for interventional drug therapy. We 29 have used a selection of traditional and experimental compounds to validate this model for anti-30 mycobacterial drug discovery. We observed that only three of the six treatments tested (Delamonid, 31 SN30527 and rifampicin) retarded the growth of M. marinum in vitro. In contrast, five of the six 32 treatments (Pretomanid, Delamanid, SN30488, SN30527 and rifampicin) retarded the growth of M. 33 tuberculosis in vitro. Importantly, these same five treatments significantly reduced the 34 bioluminescent signal from naturally infected zebrafish embryos. 35
Introduction 41
Mycobacterium tuberculosis is a deadly human pathogen that latently infects a third of the world's 42 population. Around 5-10% of these infections develop into active disease, resulting in approximately 43 1.5 million deaths per year 1 . Tuberculosis (TB) is treatable with antibiotics, albeit with extended 44 treatment times required and a high financial cost 1 , and as a result has become less prevalent in the 45 developed world, although it remains a major health issue globally 1 . However the emergence of 46 multi drug resistant (MDR-TB) and totally drug resistant (TDR-TB) isolates of M. tuberculosis has once 47 again brought TB into the spotlight for all countries and has necessitated the development of novel 48 drugs to combat this pathogen 2, 3 . A change in the global disease burden of HIV/AIDS has also added 49 impetus to this cause; the number of people co-infected with HIV and M. tuberculosis is rapidly 50 increasing globally, resulting in a destructive synergy which exponentially exacerbates the disease 51 progression of both diseases 4 . 52
Due to the difficulties and dangers involved in culturing M. tuberculosis, an airborne Biosafety Level 53 3 pathogen, faster-growing and less pathogenic mycobacterial species, such as M. smegmatis and M. 54 marinum, are routinely exploited for TB research and anti-mycobacterial drug discovery 5-8 . M. 55 marinum is a pathogen of ectotherms (fish, amphibians and reptiles) that produces a tuberculosis-56 like disease 9 . M. marinum is a close genetic relative of M. tuberculosis, with which it shares 57 conserved virulence determinants 9 , and has been known to cause granulomatous skin infections in 58 humans 10, 11 . Infection of the tropical zebrafish, Danio rerio, with M. marinum has been used to 59 develop a surrogate in vivo model of TB pathogenesis 12 useful for the rapid screening of potential 60 antimycobacterial compounds 13 . Zebrafish are genetically tractable 9 and possess a complex immune 61 system comparable to that of humans [14] [15] [16] . As a result, zebrafish have been extensively used for 62 disease modelling and drug discovery for both communicable and non-communicable diseases 13, 17-63 24 . Infection of zebrafish with M. marinum through microinjection results in the development of 64 necrotic granulomatous lesions reminiscent of human TB infection, 25, 26 lending weight to the use of 65 this model host as a surrogate for mycobacterial research and drug discovery. One drawback of the previously published infection protocols is that they require specialised equipment and a high level 67 of operator expertise 13 . 68
Bioluminescence is a biological reaction which results in the production of light via a luciferase 69 catalysed reaction. It is a naturally occurring process with several variants seen across several 70 kingdoms and has been harnessed as a reporter in both in vitro and in vivo assays 27, 28 71 Bioluminescence allows for non-invasive monitoring of luciferase-expressing bacteria within a host, 72 as the light produced by the bacterium travels through the host tissues and can be readily detected 73 [28] [29] [30] . As tagged cells only produce a signal when alive, bioluminescence is an excellent reporter to 74 rapidly assay for antimicrobial compounds, non-destructively and in real-time, in microtitre plate 75 formats using a luminometer, or in vivo using sensitive imaging equipment 28, 31-33 . 76 Zebrafish and other fish readily become naturally infected with M. marinum present in their 77 environment 34 . However it is not possible to tell which fish are infected at an early stage without 78 euthanising the animal and plating out for viable bacteria 26 . Here we use bioluminescently tagged M. 79 marinum M to establish natural infections in zebrafish embryos, utilising the light emitted by these 80 bacteria to identify which fish have become infected. We show that naturally infected fish can be 81 treated with potential anti-mycobacterial compounds and light output used as an indicator of in vivo 82 drug efficacy. 83
Materials and Methods 85
Bacterial strains and plasmids 86 Bacterial strains and plasmids used throughout this study are described in Table 1 . Bacteria were 87 transformed as previously described 35 . M. marinum strains were grown at 28℃ and M. tuberculosis 88 at 37℃, with shaking at 200rpm and 100rpm respectively, in Middlebrook 7H9 broth (Fort Richard) 89 supplemented with 10% ADC enrichment media (Fort Richard) and 0.5% glycerol (Sigma Aldrich) 90 under the appropriate antibiotic selection (kanamycin at 25µg ml -1 and hygromycin at 50µg ml -1 91 [Sigma Aldrich]). 92
93
In vitro drug testing 94 M. marinum BSG101 and M. tuberculosis BSG001 were grown without antibiotic selection to mid log 95 phase, then diluted to an optical density at 600nm (OD 600 ) of 0.01. Bacteria were aliquoted (100µl, 96 5x10 5 cfu ml -1 approx.) into the wells of a black 96 well microtitre plate (Grenier Bio-One). Test 97 compounds were dissolved in DMSO, added 1:100 to the top most well and then diluted two-fold in 98 a series down the plate ( Table 2 ). The plates were incubated at 28℃ (M. marinum) or 37℃ (M. Zebrafish (Danio rerio) embryos were obtained from natural spawnings and raised at 28℃ in E3 104 Medium (0.33 mM calcium chloride, 0.33 mM magnesium sulphate, 0.14mM potassium chloride and 105 5 mM sodum chloride). The medium was supplemented with 0.003% phenylthiourea (PTU) to inhibit 106 pigmentation when embryos were being imaged. Zebrafish embryos of the age used do not fall under the New Zealand Animal Welfare Act 1999 and so experiments did not require approval from 108 an animal ethics committee. 109 110 Natural infection of zebrafish embryos 111 M. marinum strains were grown to mid log phase (OD 600 between 0.8 and 2) without antibiotic 112 selection, washed once in E3 before being adjusted to an OD 600 of 1. The approximate concentration 113 should be around 5x10 8 cfu ml -1 ; this was confirmed by retrospectively plating inocula onto 7H11 114 supplemented with 10% OADC and 0.5% glycerol. Zebrafish embryos at 2 days post-fertilisation (dpf) 115 were dechorionated, either manually or using pronase, as previously described 36 . Groups of embryos 116 (50-300) were then placed in 9mm petri dishes containing 25ml of E3 supplemented with varying 117 concentrations of M. marinum (by varying the volume of adjusted bacteria) and incubated for 4 days 118 at 28°C. After infection, any non-internalised bacteria were removed by gently washing embryos 119 four times with fresh E3 in groups of 10 in separate wells of a 24 well tissue culture plates (BD 120 Falcon) using gentle aspiration of the media. Embryos were left in the 24 well plate overnight to 121 remove transient bacteria and then rinsed 4 times in E3 to remove the transient population. 122
Embryos were then individually placed into the wells of a clear-bottomed black 96 well microtitre 123 plate (Nunc) with 100µl of E3 and prepared for drug treatment. 124 125 Injection of zebrafish embryos 126 M. marinum strains were prepared as above. Zebrafish embryos 2dpf were manually de-127 chorionated, anaesthetised using 0.168 mg ml -1 tricaine (Sigma-Aldrich) in E3 medium 37 and infected 128 by microinjection into the caudal vein as previously described 38 . 129 130
Measurement of bioluminescence from zebrafish embryos 131
All bioluminescent measurements were carried out using a Victor X1 luminometer (Perkin Elmer) 
Results 152
Luminescence can be used to monitor zebrafish embryos naturally infected with luciferase-tagged 153
M. marinum 154
To determine if zebrafish embryos infected with bioluminescently labelled M. marinum could be 155 monitored using a luminometer, we incubated embryos (n=300) aged 1 and 2 dpf in E3 containing 156 1x10 7 cfu ml -1 of M. marinum tagged either with a modified firefly luciferase (designated M. 157 marinum BSG100) or with a modified bacterial luciferase (designated M. marinum BSG101). At 158 different time points, we removed the embryos from the M. marinum-containing media, washed 159 them in fresh media and measured light. As the firefly luciferase reaction requires luciferin as a 160 substrate, we added this exogenously (30 µg ml -1 ) when embryos were placed into the 96 well 161 plates. Bioluminescence from infected embryos did not rise above background levels until 4 days 162 post infection, with comparable levels of light emitted from BSG100 and BSG101 infected embryos 163 ( Fig. 1 ). Natural infection of embryos with M. marinum did not result in any premature deaths when 164 compared to the uninfected group. While embryos infected with M. marinum labelled with the 165 firefly luciferase (BSG100) produced more light (median maximum value of 709 relative light units 166
[RLU] (ranging from 328 to 2872)) compared to the bacterial luciferase tagged strain (BSG101) 167 (median maximum value of 446 RLU (ranging from 122 to 796)), the exogenous addition of luciferin 168 increased the time required to carry out the assay and the expense of the technique. We therefore 169 selected bacterial-luciferase tagged M. marinum M (BSG101) for further study. 170 171
Natural infection results in gill colonisation and transient gut colonisation 172
We investigated the nature and location of natural M. marinum infection of embryos using a strain 173 of M. marinum expressing the red fluorescent protein tdTomato 13 (designated BSG102). We 174 incubated the embryos with BSG102 for 4 days and then determined the location of the infecting 175 bacteria using a fluorescent microscope (Fig. 2) . We observed fluorescently tagged bacteria throughout the digestive tract, clustering around the developing gills and lower jaw of the larvae 177 ( Fig. 2 A&B) . We speculated that those bacteria present within the digestive tract could represent a 178 transient colonisation. These bacteria were seen to be removed following defecation. To test this, 179
we washed infected embryos in fresh media and incubated for a further 24 hours. After this 180 incubation period, we observed that the bacteria that were previously present within the digestive 181 tract had gone, while the bacteria associated with the developing gills were still present (Fig. 2C ). We 182 observed that the digestive tract remained clear of detectable bacteria for the majority of the 183 experiment, with some non-transient colonisation appearing approximately 11 days post infection. 184 185
Optimisation of infectious dose and infection protocol 186
In order to determine the minimum dose for establishing a traceable infection within a single 187 zebrafish embryo, we incubated embryos with concentrations of M. marinum BSG101 ranging from 188 1x10 4 to 1x10 7 cfu ml -1 and followed bioluminescence over 12 days using a luminometer. A dose of 189 1x10 7 cfu ml -1 BSG101 was the only one tested that established an infection that we could reliably 190 detect above background levels using our luminometer (Fig. 3 ). This dose resulted in approximately 191 40-60% of the exposed embryos becoming bioluminescent, depending on the experiment (data not 192 shown). When embryos were exposed to a dual bioluminescent/fluorescent tagged strain of M. 193 marinum (BSG103) and examined by fluorescence microscopy, we observed that more than 90% of 194 the embryos were infected, but only half of these could be detected by luminometry (data not 195 shown). 196 In an effort to reduce the time required to process embryos for infection, we investigated the effect 197 of manual versus chemical dechorionation (treatment with pronase). We observed that pronase 198 treatment reduced the proportion of infected embryos detectable by luminometry (45% for manual, 199 7% for pronase) and light levels from infected embryos were also consistently lower (20-150 RLU for 200 manual, 20-76 RLU for pronase). For these reasons, we adopted the following optimised protocol for 201 further experiments: 1) manual dechorionation of embryos 2 dpf, 2) immersion in media containing 202 1x10 7 cfu ml -1 M. marinum for 4 days at 28°C, 3) wash in fresh media and incubation for a further 24 203 hours at 28°C, 4) transfer of individual embryos to the wells of a black 96 well plate using a sterile 204 plastic pasteur pipette for measurement of light and drug intervention studies. infected through microinjection into the caudal vein with a subset of the compounds (Fig. 4) . We 214 considered all injected embryos as infected, whereas we only selected embryos with observable 215 light emission after natural infection for use in drug intervention studies. For naturally infected 216 embryos we used reduction in light emission as a surrogate measure of anti-mycobacterial activity; 217 for injected embryos, we measured drug efficacy by embryo survival. We also exposed in vitro 218 grown M. marinum and M. tuberculosis to the same compounds. 219
We observed that at the concentration used, only three of the six treatments tested (Delamonid, 220 SN30527 and rifampicin) retarded the growth of M. marinum BSG101 in vitro (as shown by a lack of 221 increase in bioluminescence) ( Fig 5A) . In contrast, five of the six treatments tested (Pretomanid, 222 Delamanid, SN30488, SN30527 and rifampicin) retarded the growth of M. tuberculosis BSG001 in 223 vitro ( Fig 5B) . Interestingly the same five treatments tested (Pretomanid, Delamanid, SN30488, 224 SN30527 and rifampicin) significantly reduced the bioluminescent signal from naturally infected 225 zebrafish embryos (p<0.001, Kruskal Wallis test with Dunns multiple comparisons) (Fig. 4A) . The data 226 is summarised in Table 3 . Similarly, we observed a 90% survival rate for BSG101 injected embryos 227 treated with Pretomanid and Delamanid, compared to 20% survival of untreated injected embryos 228 or those treated with SN30982 or rifampicin (Fig. 4B) . 229
230
Discussion 231
There is a clear and desperate need for new medicines to treat TB. As working with M. tuberculosis 232 limits research and preclinical drug development to those laboratories around the world with the 233 resources and facilities to safely handle the bacterium, non-tuberculous mycobacteria such as M. 234 marinum are widely used as surrogates 5, 7, 41, 42 . A major drawback of using M. marinum for 235 antimycobacterial compound screening is that the in vitro resistance profile of the bacterium is very 236 different to M. tuberculosis. This difference can be observed in the drastically different MIC values 237 for the compounds tested against the two organisms in this study ( Table 2) . Two of the compounds 238 (Pretomanid and SN30488) were not effective against M. marinum but were effective against M. 239 tuberculosis. This means that screening compounds for activity against M. marinum in vitro runs the 240 risk of missing potential anti-TB agents. 241
Infection of zebrafish, either as adults or as embryos, by injection with M. marinum has proved to be 242 a useful model for studying mycobacterial pathogenicity and for drug screening 13, 43, 44 . However, 243 current infection protocols require specialised equipment and a high level of operator expertise. We 244 first wanted to establish whether it was possible to infect zebrafish embryos by exposure to M. 245 marinum in the media, and to monitor infection dynamics using bioluminescence. We determined 246 that incubation for four days in a petri-dish containing 10 open-ended tube by 4 dpf 45 . The initial digestive tract colonisation was found to be transitory, 252 although at later stages a non-transitory colonisation was observed. It is unsurprising that the 253 embryos could be infected via bathing, as this should represent one of the ways that zebrafish could 254 become naturally infected in the wild; however without the use of bioluminescence to visualise M. 255 marinum, the easy identification of infected embryos would not be possible. We observed that the 256 proportion of embryos which became infected varied depending on the housing conditions. Initially 257 embryos were housed in groups of 50 for infection but this resulted in a low proportion of 258 measurable infections. When we increased the number to 300, the proportion of embryos with a 259 measurable infection rose to approximately 40%. We speculate that this is due to the increased 260 motion of the fish in the media allowing for greater mixing. Another possibility is that M. marinum 261 may phenotypically change as it travels through the embryo gut, making it more infectious. Such 262 hyperinfectivity has been reported for Vibrio cholera and Citrobacter rodentium 46-48 263 As several bioluminescent reporter systems exist, we wanted to establish which one would give the 264 best results for this assay. We compared mycobacterial optimised bacterial luciferase (lux) and the 265 codon-optimised red shifted firefly luciferase (RTluc) 49 . The bacterial lux construct contains all the 266 required genes to make both the substrate and the catalytic enzyme to produce light. In the case of 267 the firefly luciferase, the substrate has to be added exogenously. While M. marinum tagged with the 268 firefly luciferase did produce higher levels of light, this was not enough to compensate for the 269 increased cost to the assay, both in terms of expense and time as a result of having to add the 270 exogenous substrate. We chose to use M. marinum tagged with bacterial lux through-out to produce 271 as streamlined and economic an assay as possible. 272
We investigated whether the assay could be accelerated by using pronase treatment to 273 dechorionate embryos. While pronase treatment did reduce the time required to prepare embryos, 274 more bacteria were needed to establish an infection compared to the dose needed to infect 275 manually dechorionated embryos. Similarly, the proportion of infected embryos with visible 276 bioluminescence was also reduced. One possible explanation for this difference could be that pronase treatment may result in an increased inflammatory reaction within the embryos, resulting in 278 greater initial killing of the bacteria. 279
The optimised natural infection assay protocol we have established requires manual dechorination 280 of zebrafish embryos two days post fertilisation, followed by bathing with 1x10 7 cfu ml -1 M. marinum 281 for 4 days. Embryos are then removed from the infected media, washed and placed in fresh media 282 and kept for a further overnight to allow for the clearance of transiently colonising bacteria. After a 283 further wash, embryos can be housed within individual wells of a clear bottom, black 96 well plate 284 for measurement of infection dynamics using bioluminescence. We investigated whether the 285 optimised natural infection assay could be applied to the testing of anti-mycobacterial compounds. 286
Four of the six compounds we tested reduced the luminescence from infected embryos to below 287 background levels. When the same compounds were tested in the caudal vein-injection model, 288 which uses embryo survival as an indicator of bacterial clearance, three of the four compounds were 289 also identified as being effective. 290
Overall this study has demonstrated that it is possible to carry out high throughput in vivo drug 291 screening in the zebrafish model using embryos naturally infected with bioluminescent M. marinum 292 M. Natural infection is quicker than injection and requires less expertise. Interestingly, not all of the 293 injected embryos had detectable light levels and with the fluorescently tagged M. marinum up to 294 90% of the naturally infected embryos had visible signs of infection (data not shown). Embryos can 295 be screened in 96 well plates and drug efficacy rapidly identified over the course of 10 days. Through 296 the use of a luminometer with a plate stacker this process can be semi-automated to reduce the 297 hands on time. While this is moderately slower than previously reported automated robotic systems, 298 it is also a fraction of the cost. The result is an assay that can be carried out by a wide variety of 299 
